Clinical Trial Update: A Study to Evaluate the Esophageal Stenosis Inhibition Effects of CLS2702C/CLS2702D After Endoscopic Submucosal Dissection (ESD) in Patients With Superficial Esophageal Cancer in the Steroid Administration Risk Group [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating CLS2702C/CLS2702D to inhibit esophageal stenosis after endoscopic submucosal dissection in superficial esophageal cancer was terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Superficial Esophageal Cancer

Drugs mentioned

• CLS2702C
• CLS2702D

Snippet

Sponsor: CellSeed Inc. | Conditions: Superficial Esophageal Cancer | Phase 3 | Status: TERMINATED